Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells

Journal of Nuclear Medicine

Volumn 40, Issue 4, 1999, Pages 667-671

  Geldof, Albert A ^a   De Rooij, Laurens ^a   Versteegh, Richard T ^a   Newling, Donald W W ^a   Teule, Gerrit J J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

186Re hydroxyethylidene diphosphonate; Combination therapy; In vitro; Prostate cancer; Synergism

Indexed keywords

CISPLATIN; ETIDRONIC ACID RE 186; ETIDRONIC ACID; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; RADIOSENSITIZING AGENT; RHENIUM; RHENIUM-186 HEDP;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; DRUG EFFICACY; MALE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; ANIMAL; CELL CULTURE; DRUG SCREENING; PROSTATE TUMOR;

ANIMALS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; ETIDRONIC ACID; MALE; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOISOTOPES; RATS; RHENIUM; TUMOR CELLS, CULTURED;

EID: 0032588564     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Maxon HR, Schroder LE, Thomas SR, et al. Re-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormonal-resistant prostate cancer. Radiology. 1990;176:155-159.
2. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
3. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839-1844.
4. Holmes RA. Radiopharmaceuticals in clinical trials. Semin Oncol. 1993;20(suppl 2):22-26
5. Geldof AA, van den Tillaar PLM, Newling DWW, Teule GJJ. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model. Urology. 1997;49:795-801.
6. Mertens WC, Porter AT, Reid RH, Powe JE. Strontium-89 and low dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med. 1992;33:1437-1443.
7. Geldof AA, Slotman BJ. Radiosensitizing effect of cisplatin in prostate cancer cell lines. Cancer Lett. 1996;101:233-239.
8. Geldof AA, Rao BR, de Voogt HJ. Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Anticancer Res. 1986;6:837-840.
9. Raaphorst GP, Wang G, Stewart D, Ng CE. Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Int J Radiat Biol. 1996;69:623-631.
10. Chou TC, Talalay P. Quantitation analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul. 1984;22:27-55
11. Mertens WC. Radionuclide therapy of bone metastases: Prospects for enhancement of therapeutic efficacy. Semin Oncol. 1993; 20(suppl 2):49-55.
12. Sciuto R, Maini CL, Tofani A, Fiumara C, Scelsa MG, Broccatelli M. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun. 1996;17:799-804.
13. Dewit L. Combined treatment of radiation and cis-diaminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 1987;13:403-426.
14. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomittant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524-530.
15. Begg AC. Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys. 1990;19:1183-1189.
16. Fu KK. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer. 1985;55:2123-2130.
17. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys. 1984;10:1473-1478.
18. Quirijnen JMSP, Han SH, Zonnenberg BA, et al. Efficacy of Rhenium-Etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med. 1996;37:1511-1515.